Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- James Nathanielsz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 3.33
- Country
- AU
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -19.61
Financials
Net Income
$-4.57MEBITDA
$-3.45MFree Cash Flow
$-1.70MEPS (diluted)
$-1.38Shares Outstanding (diluted)
3.31M+34.8%Operating Expenses
$3.45MCash & Debt
$832.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-18.86M | $-17.62 |
| 2025 | $0.00 | $-58.92M | $-371.25 |
| 2024 | $0.00 | $-1.82M | $-35523.75 |
| 2023 | $0.00 | $-2.66M | $-781709.75 |
| 2022 | $0.00 | $-2.66M | $-27986891.75 |
| 2021 | $0.00 | $-2.03M | $-20000.00 |
| 2020 | $0.00 | $-4.74M | $-4811228.75 |
| 2019 | $0.00 | $-5.76M | $-274239389.25 |
| 2018 | $0.00 | $-7.04M | $-4468737303.25 |
| 2017 | $0.00 | $-7.87M | $-28018162393.25 |
| 2016 | $0.00 | $-9.41M | $-6.00 |
| 2015 | $0.00 | $-3.41M | $-6.00 |
| 2014 | $0.00 | $-829.6K | $-3.50 |
| 2013 | $0.00 | $-1.44M | $-6.25 |
Valuation
PPCBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·7d ago·Neutral
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results "The Company is poised to capitalize on the foundation set
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
… for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patie…
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
…h for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human (FIH), Phase 1b clinical s…
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread
View source ↗
Insider trading
Open-market buys and sells by PPCB officers and directors.
- Bought
- $50k
- Sold
- $60k
1 trade
5 trades
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsolddirector, 10 percent owner, officer: Chief Executive Officer·250,000 @ $0.20·$50k·Sep 4, 2012·filing
- Nathanielsz James Andrewboughtdirector, 10 percent owner, officer: Chief Executive Officer·250,000 @ $0.20·$50k·Aug 23, 2012·filing
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PPCB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.